Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.

What Was Tested

The paper reports a study of Antihypertensive Agents in the context of low blood pressure and orthostatic hypotension, published as a randomized controlled trial.

Azilsartan medoxomil (AZL-M) is a unique angiotensin II receptor blocker (ARB) under development for the treatment of hypertension.

Baseline 24-hour mean systolic BP was similar (approximately 145.6 mm Hg) in each group.

Who Took Part

The abstract describes 984 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and multicenter.

Because people in this Antihypertensive Agents study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Antihypertensive Agents study, the assignments were hidden from both participants and investigators until the end.

Running at several centres spread the Antihypertensive Agents study over different clinics and patient groups.

What Was Measured

Topics PubMed links to this paper include Age Factors, Antihypertensive Agents, Benzimidazoles, Biological Availability, Blood Pressure, Blood Pressure Monitoring, Ambulatory and Drug Monitoring.

What This Means in Plain Language

The paper is a randomized, double-blind and multicenter study of Antihypertensive Agents in 984 patients in people with low blood pressure and orthostatic hypotension.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2011 (Journal of clinical hypertension (Greenwich, Conn.)), a journal based in United States.

More context: Low blood pressure and orthostatic hypotension research.